NCT05838625CompletedPhase 3
Study of Two Digital Therapeutics for the Treatment of Experiential Negative Symptoms of Schizophrenia
A Randomized, Multicenter, 16-week Study to Evaluate the Efficacy and Safety of Two Prescription Digital Therapeutics as an Adjunct to Standard-of-Care Antipsychotic Therapy in Adult and Late Adolescent Participants With Experiential Negative Symptoms of Schizophrenia
Source: ClinicalTrials.gov · Last updated 12 Jun 2026
Brief summary (registry, in English)
This study evaluates the efficacy of two prescription digital therapeutics (PDT) in addition to standard of care (SOC) therapy for the treatment of experiential negative symptoms of schizophrenia in late adolescents and adults.
- Status (registry)
- Completed
- Phase (registry)
- Phase 3
- Study type
- Interventional
- Enrollment
- 464 (actual)
- First submitted
- 20 Apr 2023
- Start date
- 31 Mar 2023
- Primary completion date
- 20 Jun 2025
- Lead sponsor
- Click Therapeutics, Inc.
- Diseases
- Schizophrenia
- NCT number
- NCT05838625
What you commit to
- Study type: Interventional · Phase 3
- Participants enrolled: 464
- From 31 Mar 2023 to the primary completion date, 20 Jun 2025
- 54 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Is currently treated with more than two antipsychotic medications (including more than two dosage forms).
Other
- A participant will not be eligible for study entry if any of the following criteria are met:
- Meets DSM-5, for diagnoses not under investigation.
- Has participated in a CT-155 clinical study.
Who the study is looking for
- A participant will be eligible for entry into the study if all of the following criteria are met:
- Has a primary diagnosis of schizophrenia.
- Is on a stable dose of antipsychotic medication(s).
- Has obtained an average score of ≥2 (moderate to severe) in at least two of the three CAINS-MAP domains (Social, Work, or Recreational).
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (54)
Sites in registry order. Pick your city on the disease page to sort them by distance.
Related publications
- A Digital Therapeutic Intervention for Negative Symptoms of Schizophrenia: A Randomized Clinical Trial.JAMA Netw Open · 2026 · PMID 42789268
This page is information, not medical advice. Discuss any trial with your doctor.